Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Cellular and molecular mechanisms of bladder immune responses to uropathogens and therapeutics

Funder: European Commission

Funding period
EUR 100 K
USD 121 K
Funding amount
Abstract
"The bladder is a unique mucosal barrier devoid of colonizing microbiota and organized lymphoid structures. This research project will examine bladder immunobiology, specifically as it relates to urinary tract infection (UTI) and bladder cancer. Notably, UTI is second only to respiratory infection in prevalence, and bladder cancer is the fifth leading cause of cancer. While commonalities between UTI and bladder cancer may not be immediately apparent, the most effective treatment for transitional cell carcinoma is intravesical instillation of BCG, or the direct introduction of bacteria into the bladder lumen. We will investigate bladder immune responses following uropathogenic E. coli (UPEC) or BCG instillation, with the aim to identify how dendritic cells (DCs) and T cells behave following bacterial interactions with what is a unique mucosal surface in the body. Specifically, we will test the hypotheses that (i) bladder-resident macrophages acquire UPEC antigen in the bladder and sequester it from DCs, limiting antigen presentation, while lymph node-resident DCs capture disseminated BCG and efficiently present it; and (ii) DCs that do capture UPEC antigen lack the ability to cross-present antigen whereas BCG-antigen loaded DCs have a greater capacity to activate CD8+ T cells. These hypotheses are based on animal model and clinical observations and will help establish a scientific foundation for exploring strategies to enhance UPEC antigen-specific responses, taking lessons from BCG’s capacity to induce cross-priming. The goal of these studies is to understand the differential outcomes in adaptive immune responses to BCG or UPEC thereby defining strategies to enhance clearance of UPEC and improve the efficacy of BCG-mediated tumor immunity. My dual training as a microbiologist and immunologist will ensure that attention is given to both the bacterium and the host in defining the differential regulation governing the respective disease processes."
Similar projects All >
Sorted by: Start Date
Project list item
Intravesical delivery of an Fc-enhanced CD40 agonist antibody for the treatment of bladder cancer

Bladder Cancer Advocacy Network to Jeffrey Ravetch, David Knorr

USD 300,000
2020 - 2022
Project list item
Defining NRF2 induced tumor invasion in bladder cancer

Bladder Cancer Advocacy Network to Yuki Kita, William Youngkwan Kim, Bernard Weissman

USD 50,000
2020 - 2021
Project list item
Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer

National Cancer Institute to NINA BHARDWAJ, JUN ZHU, MATTHEW GALSKY

USD 703,400
2020 - 2025
Project list item
Chimeric RNAs and their implication in lymphatic metastasis of bladder cancer

National Cancer Institute to HUI LI

USD 205,913
2020 - 2025
Project list item
CD40 agonism for the treatment of bladder cancer

National Cancer Institute to CHRISTOPHER STUART GARRIS

USD 64,554
2020 - 2023

System

Categories
  • FOR (ANZSRC)

    1107 Immunology

  • FOR (ANZSRC)

    1108 Medical Microbiology

  • RCDC

    Cancer

  • RCDC

    Infectious Diseases

  • RCDC

    Urologic Diseases

  • HRCS HC

    Infection

  • HRCS HC

    Cancer

  • HRCS RAC

    2.1 Biological and endogenous factors

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Basic Science